Zoetis, Inc. (ZTS)
81.03
-0.97
(-1.18%)
USD |
NYSE |
Oct 23, 16:00
81.00
-0.03
(-0.04%)
After-Hours: 20:00
Zoetis Enterprise Value : 41.12B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 41.12B |
| October 22, 2026 | 41.52B |
| October 21, 2026 | 40.54B |
| October 20, 2026 | 40.71B |
| October 19, 2026 | 40.52B |
| October 16, 2026 | 40.44B |
| October 15, 2026 | 40.04B |
| October 14, 2026 | 38.74B |
| October 13, 2026 | 38.33B |
| October 12, 2026 | 38.89B |
| October 09, 2026 | 38.54B |
| October 08, 2026 | 37.83B |
| October 07, 2026 | 37.19B |
| October 06, 2026 | 37.10B |
| October 05, 2026 | 37.14B |
| October 02, 2026 | 36.42B |
| October 01, 2026 | 36.18B |
| September 30, 2026 | 36.48B |
| September 29, 2026 | 36.68B |
| September 28, 2026 | 37.15B |
| September 25, 2026 | 36.99B |
| September 24, 2026 | 36.66B |
| September 23, 2026 | 37.22B |
| September 22, 2026 | 37.74B |
| September 21, 2026 | 37.10B |
| Date | Value |
|---|---|
| September 18, 2026 | 37.13B |
| September 17, 2026 | 37.80B |
| September 16, 2026 | 37.80B |
| September 15, 2026 | 37.97B |
| September 14, 2026 | 38.07B |
| September 11, 2026 | 37.78B |
| September 10, 2026 | 37.74B |
| September 09, 2026 | 37.92B |
| September 08, 2026 | 38.03B |
| September 04, 2026 | 38.96B |
| September 03, 2026 | 39.16B |
| September 02, 2026 | 39.11B |
| September 01, 2026 | 39.56B |
| August 31, 2026 | 39.49B |
| August 28, 2026 | 39.59B |
| August 27, 2026 | 38.63B |
| August 26, 2026 | 39.67B |
| August 25, 2026 | 39.57B |
| August 24, 2026 | 39.52B |
| August 21, 2026 | 39.75B |
| August 20, 2026 | 38.63B |
| August 19, 2026 | 39.32B |
| August 18, 2026 | 38.19B |
| August 17, 2026 | 37.78B |
| August 14, 2026 | 38.12B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 405.39B |
| Phibro Animal Health Corp. | 2.281B |
| Eli Lilly & Co. | 1.245T |
| Pfizer Inc. | 222.94B |
| Bristol Myers Squibb Co. | 159.59B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 691.00M |
| Revenue (Quarterly) | 2.468B |
| Total Expenses (Quarterly) | 1.777B |
| EPS Diluted (Quarterly) | 1.654 |
| Gross Profit Margin (Quarterly) | 71.47% |
| Profit Margin (Quarterly) | 28.00% |
| Earnings Yield | 7.50% |
| Operating Earnings Yield | 10.27% |
| Normalized Earnings Yield | 7.754 |